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Klhl14-AS is a long noncoding RNA expressed since early specification of thyroid bud and is the most 
enriched gene in the mouse thyroid primordium at E10.5. Here, we studied its involvement in thyroid 
carcinogenesis, by analyzing its expression in cancer tissues and different models of neoplastic 
transformation. Compared to normal thyroid tissue and cells, Klhl14-AS was significantly 
downregulated in human thyroid carcinoma tissue specimens, particularly the anaplastic histotype, 
thyroid cancer cell lines, and rodent models of thyroid cancer. Downregulating the expression of 
Klhl14-AS in normal thyroid cells decreased the expression of thyroid differentiation markers and cell 
death and increased cell viability. These effects were mediated by the binding of Klhl14-AS to two 
microRNAs, miR-182-5p and miR-20a-5p, which silenced PAX8 and BCL2, both essential players of 
thyroid differentiation. miR-182-5p and miR-20a-5p were upregulated in human thyroid cancer and 
thyroid cancer experimental models and their effects on Pax8 and Bcl2 were rescued by Klhl14-AS 
overexpression, confirming Klhl14-AS as a ceRNA for both PAX8 and BCL2.  
This work connects deregulation of differentiation with increased proliferation and survival in thyroid 
neoplastic cells and highlights a novel ceRNA circuitry involving key regulators of thyroid physiology. 
 
Significance  
This study describes a new ceRNA with potential tumor suppression activity and helps us better 








The widest and least known part of human genome is extensively transcribed in noncoding RNA 
molecules, generally classified in short and long noncoding RNA based on their length. Long 
noncoding RNAs (lncRNAs) are broadly defined as RNA molecules longer than 200 nucleotides that 
appear to lack protein-coding potential (1). LncRNAs are functional molecules, acting through different 
mechanisms that can be generally reassumed into three types: guides, scaffolds and molecular decoys. 
Guides are able to target chromatin modifying complex or transcription factors to specific loci; 
scaffolds act as platforms to assemble protein complexes; decoys can bind to other regulatory RNAs or 
proteins to sequester them away to their targets (1). One abundant and well-studied class of short RNAs 
are microRNAs (miRNAs), 22-23 nt long RNA molecules that guide RNA-Induced Silencing 
Complexes (RISC) on target mRNAs and lncRNAs, to either block mRNA translation or induce target 
RNA decay (2,3). Several lncRNAs are able to regulate the expression of other RNAs sharing 
responsive elements for the same miRNA (MREs), thus acting as competitive endogenous RNA 
(ceRNA) (4-6). Similarly to protein-coding genes and miRNAs, lncRNAs are aberrantly expressed in 
cancer, thus affecting the complex regulatory circuits in which they are involved (7). The miRNA 
sponge activity of several lncRNAs has been shown in different kinds of cancer, including thyroid 
cancer, where they play either oncogenic or tumor suppressor roles (8-13).  
 Klhl14-AS is a long noncoding RNA identified as the most enriched transcript in thyroid bud at E10.5 
day of mouse development (14). We recently demonstrated that it is expressed in several mouse adult 
tissues including thyroid (15). The expression of Klhl14-AS at early stages of thyroid development 
suggested a possible role in mechanisms regulating cell differentiation and proliferation, similarly to 
what described for other lncRNAs (4,16). Therefore, in this study we have investigated the expression 






transformation, either in vitro and in vivo, showing that this lncRNA is strongly repressed in 
transformed thyroid cells. We also report that Klhl14-AS expression is necessary for maintaining the 
differentiated phenotype in normal thyroid cells, likely acting as decoy for two miRNAs upregulated in 
thyroid cancer, targeting two important regulators of thyroid physiology, Pax8 and Bcl2.  
Overall, our results highlight a role of Klhl14-AS in the maintenance of normal thyroid phenotype, 
showing its contribution to the loss of differentiation and the increase of cell proliferation/survival in 
thyroid cancer. 
 
Materials and Methods 
 
Human thyroid samples 
Human thyroid carcinoma specimens used was provided by the Service d’Anatomie et Cytologie 
Pathologiques, Centre de Biologie Sud, Groupement Hospitalier Lyon Sud, Pierre Bénite, France. The 
activity of biological samples conservation was declared under the number DC-2011-1437 to the french 
Ministry of Research, to the committee of people’s protection of south-east IV and to the Health 
Regional Agency. The activity of biological material cession was agreed upon by the french Ministry 
of Health under the number AC-2013-1867. 
 
Mice 
TetO-BrafV600E and Tg-rtTA transgenic mice were obtained from Prof JA Fagin at Sloan-Kettering 
Institute for Cancer Research (NY, USA), where they have been generated (17), and were crossed to 
obtain the double transgenic mice Tg-rtTA; TetO-BrafV600E.  
Mice were maintained under pathogen-free conditions and controlled temperature, humidity, and light 






approved (D.M. 78/213-A, and 12/2018-UT) Animal Facility of the Università Federico II, Naples, 
Italy. Tg-rtTA-TetO-BrafV600E transgenic mice were fed with a 2500 mg/kg Doxycycline 
supplemented fodder for one week. These studies have been approved by the Institutional Animal Care 
and Use Committee (IACUC) of University of Naples Federico II and by the Italian Ministry of Health 
with protocol n° 2013/0078506. 
 
Cell culture and transfection 
HeLa, Nthy-ori 3-1, BCPAP, TPC1, 8505C, CAL62, WRO and ACT-1 cell lines were cultured in 
DMEM High Glucose supplemented with 10% Fetal Bovine Serum (Hyclone Thermo Fisher 
Scientific) and 1% pen-strep (EuroClone). FRTL-5, ERTMRASV12FRTL-5 and H-RASV12FRTL-5 
were grown in Coon’s modified F12 medium (EuroClone) supplemented with 5% calf serum (Hyclone 
Thermo Fisher Scientific) and six hormones as described (18). All cell lines used in this study were 
originally obtained by public cell banks (ATCC and ECACC) and frozen in large stocks before 
reaching 10 passages after recovery. Experiments were performed by using vials from the same 
passage and before reaching five passages after thawing. Cell identity was verified by DNA 
fingerprinting using AmpFlSTR® Identifiler®PCR Amplification Kit (Applied Biosystem). STR 
profiles were compared to public databases by using Cellosaurus resource at ExPASy Bioinformatics 
Resource Portal (https://www.expasy.org). Mycoplasma infection was regularly checked by Hoechst 
staining and observation at 500X magnification. 
Tamoxifene was used at 0.4 nM to induce Ras activation. MAPK inhibitor U0126 was used at 25µM. 
Actinomycin D was used at 1µg/mL. Locked nucleic acid oligos (Exiqon Antisense LNA GapmeRs in 
vitro Standard), siRNA (riboxx life sciences siRMA duplexes bundle S) and miRNA inhibitor (Exiqon 
miRCURY LNA inhibitors) were transfected at 100nM, 100nM and 75nM respectively. miRNA 






expression analysis and at 25nM for Luc assays. 50 ng of pCEFL-Pax8 and -Bcl2 or 150 ng of pCEFL-
Klhl14-AS were used for transfections in 6-wells plates. 
Klhl14-AS Antisense LNA GapmeRs were designed through Exiqon tool that generated the following 
sequences. Standard negative control is provided by the manufacturers. 
Klhl14-AS LNA: AAGTGAGTGGAGAGGA  
KLHL14-AS LNA: GTAAAGTGAGTCGAAA 
Dicer specific siRNA was generated by riboxx tool, generating a duplex with guide (see below) and 
passenger sequences. Standard negative control is provided by the manufacturers. 
Dicer siRNA guide sequence: UUAUUCUGCAGACUUUCCCCC 
All the transfections were performed using Lipofectamine 2000® (Thermo Fisher Scientific) according 
with manufacturer’s specifications and cells were harvested at 48h, except for Actinomycin D treated 
cells, harvested at 24h. 
 
Gene expression analyses 
Total RNA was isolated from cultured cells, mouse thyroids and human biopsies using Trizol (Sigma 
Aldrich) reagent and cDNA was generated with SensiFAST cDNA Synthesis Kit (BIOLINE BIO-
65054), according to manufacturer’s specifications. Quantitative Real-Time PCR (qRT-PCR) was 
performed with iTaq Universal SYBR Green Supermix (Bio-Rad) using gene specific oligos (le S1). 
18S, Ciclofillin and Abelson were used as endogenous controls for detection of lncRNA and mRNAs in 
human, rat and mouse samples, respectively. 
MiRNA-specific Reverse Transcriptase and Real-Time PCR (RT-PCR) were carried out using 
TaqMan®  MicroRNA Reverse Transcription kit, TaqMan® (Applied Biosystems 4366596)  TaqMan 
MicroRNA Assays (Applied Biosystems 4427975) and TaqMan® Universal PCR MasterMix, No 






was used as endogenous control for detection of miRNAs. 
qRT-PCR reactions were carried out in BioRad CFX96 C1000 Touch thermal cycler. RT-PCR were 
performed in BioRad T100 thermal cycler, run on agarose gels and captured by BioRad CHEMIDOC 
XRS equipped with QuantityOne software version 4.6.5. 
In situ hybridization analysis were performed as described (15). 
 
Expression vectors 
Rat Bcl2 CDS and mouse Klhl14-AS transcript isoform B (15) were amplified from FRTL-5 and 
mouse thyroid cDNA, respectively, using PWO SuperYeld DNA polymerase (Roche 11 644 947 001) 
according to manufacturer's specification. Primers sequences are reported in Table S2. Both regions 
were then cloned in pCEFL expression vector (38121 Addgene). Bcl2 was cloned in HindIII and XbaI 
sites and Klhl14-AS in KpnI and XbaI sites. The constructs were isolated from E.coli competent cells 
(Mix & Go! Competent Cells- Zymo 5a, Zymoresearch T3007) using the GenEluteTM HP Plasmid 
Maxiprep kit (Sigma-Aldrich, NA0310). Pax8 expression vector has been described (19).  
 
Immunofluorescence assay 
Control and Klhl14-AS silenced-FRTL-5 were fixed and analyzed for Ki67 staining according to the 
following protocol: 
20' in 4% paraformaldehyde, 3X 5' 1XPBS, 10' 0,5% v/v Triton-1XPBS, 3X 5' 1XPBS, 30' 0,5% W/v 
BSA-1XPBS , 3X 5' 1XPBS, o.n 4°C  Ki67 antibody (Abcam ab16667), 3X 5' 1XPBS , 1h RT anti-
rabbit antibody (Alexa Fluor, ThermoScientific A-21441,), 3X 5' 1XPBS, 10' Hoechst,  mounting with 
PBS:Glycerol. Confocal microscopy and overlay analysis were performed on a Zeiss Meta 710 








Sequences for human, mouse, rat and zebrafish, Klhl14-AS transcripts were taken from Ensembl v94. 
For zebrafish additional antisense transcripts were obtained from published studies (20,21). The region 
of conservation (~100 bases) overlapping the antisense transcripts was identified on the UCSC browser 
using Multiz alignment conservation tracks for each species as follows: 
- Human  
(hg38 Multiz 100way http://hgdownload.soe.ucsc.edu/goldenPath/hg38/multiz100way/maf/) 
- Mouse  
(mm10 Multiz 60way http://hgdownload.soe.ucsc.edu/goldenPath/mm10/multiz60way/maf) 
- Rat  
(rn6 Multiz 20way http://hgdownload.cse.ucsc.edu/goldenPath/rn6/multiz20way/rn6.20way.maf.gz) 
- Zebrafish  
(zv9 Multiz8way http://hgdownload.soe.ucsc.edu/goldenPath/danRer7/multiz8way/multiz8way.maf.gz) 
 
Further the conserved region was cross-verified by multiple alignment of the antisense transcripts from 
human, mouse, rat and zebrafish using Mafft L-INS-i (22).  Prediction of miRNA target sites on the 
antisense transcripts and in the region of conservation was performed by Pita (23) against miRNAs 
sequences for each species (ftp://mirbase.org/pub/mirbase/CURRENT/mature.fa.gz) (24). 
Predicted MREs on the Bcl2 and Pax8 transcripts were identified by searching for rno-miR-182 and 
rno-miR-20a-5p canonical (7-8-nt) and marginal (6-nt) seed-matched sites (25) using a custom Perl 
script. 
 
Luciferase reporter vectors and assays 
Highly conserved region (HCR) of Klhl14-AS and MREs containing regions (MCR) of Pax8 and Bcl2 
were amplified from FRTL-5 cDNA (oligos in Table S2), using PWO SuperYield DNA Polymerase 
(Roche 04 340 850 001) according to manufacturer's specifications. The amplified products were 
cloned into the pGL3 Control Vector (Promega E1751) in XbaI sites in both possible directions, with 






(Promega E2261) was used to normalize Luc activity. Protein extracts were obtained and analyzed 
using the Passive Lysis buffer (Promega E1941), Luciferase assay system (Promega E4550) and 
Renilla Luciferase assay system (Promega E2820) according manufacturer’s instructions. Luciferase 




Cell viability of control and Klhl14-AS LNA transfected FRTL-5 and Nthy-ori 3-1 was evaluated by 
Trypan Blue exclusion assay and MTS assay. 48 hours after transfection cells were stained with Trypan 
Blue (BioRad 1450013) following manufacturer's instructions and viable and dead cells were counted 
by using a manual hemacytometer. Then, 4 x 10
4
 FRTL-5 and 10
4
 Nthy-ori 3-1 of both control and 
silenced cells were re-plated and cultured for additional 24 hours. MTS assay was performed using 
CellTiter96 ® Aqueous One Solution Cell Proliferation Assay (MTS) (Promega G3580) according to 
manufacturer's specifications and measured by SYNERGY HT microplate reader (Biotek) equipped 
with software Gen5 version 2.05. 
 
RNA pull-down 
RNA pull-down was performed in FRTL-5 cells as already described (12), except that magnetic beads 
(Streptavidin MagneSphere Paramagnetic Particles, Promega) were saturated with 25mg of tRNA for 
30' before incubation of 500g of supernatant together with seven biotinylated DNA oligonucleotides 
for 2 hrs at R.T. Klhl14-AS oligo sequences are reported in table S3, LacZ control oligos have already 








Total proteins were extracted using lysis buffer (NaCl 150mM, Tris HCl 50mM, MgCl2 5mM, Na 
deoxycolate 0.5 %, SDS 0.1%, Triton X-100 1%). DTT 0.1 mM, PMSF 0.5 mM, protease inhibitor 
cocktail (Sigma Aldrich P8340) and phosphatase inhibitor (Sigma Aldrich P0044) were freshly added 
to the buffer. 20g were loaded for western blot. Immunoblots were incubated with primary antibodies: 
PAX8 (26) BCL2 (Santa Cruz 7382), AGO2 (Abcam ab32381), phospho-ERK (cell signaling 9101), 
ERK (cell signaling 9102), GAPDH (Immuno Chemical G4-C5-N) and ACTIN (A5441, Sigma-





 Western Blotting Detection Reagents (GE Healthcare 









Klhl14-AS expression is downregulated in human thyroid cancer and experimental models of 
neoplastic transformation  
To investigate the involvement of KLHL14-AS in thyroid carcinogenesis, we analyzed its expression in 
twelve pairs of papillary thyroid cancer (PTC) specimens and their healthy adjacent tissue (HT), by 
qRT-PCR. All tumor samples were compared to all healthy ones, showing that PTCs values are 
characterized by a median lower with respect to that of HTs (Fig 1A). The coupling of each tumor 
sample with its normal counterpart, shows that KLHL14-AS expression is highly variable between 
samples, with a clear trend of reduction in eight out of twelve (67%) PTC with respect to the normal 
tissue (Fig. S1A). Subsequently, we analyzed nine anaplastic thyroid cancer (ATC) samples, for which 
healthy thyroid tissue is unavailable as ATC patients usually do not undergo surgery (27,28). 
Therefore, ATC tissues were compared to a pool of independent healthy thyroid samples. Figure 1B 
shows that KLHL14-AS, althoug at different extents, was downregulated in all ATC biopsies analyzed 
respect to normal thyroids.  
KLHL14-AS levels were further investigated in cell lines of human thyroid cancers of different 
histotypes: BCPAP and TPC1 (PTC), WRO (follicular carcinoma), Cal62 and 8505C (ATC). KLHL14-
AS resulted severely downregulated in all the lines analyzed, with the most pronounced decrease in 
ATC cell lines, Cal62 and 8505C (Fig 1C), consistently with the results obtained on ATC tissues. 
These observations prompted us to explore Klhl14-AS regulation in experimental thyroid cancer 
models, both in vitro and in vivo. As in vitro models, we used two different cell lines obtained from 











 FRTL-5 is a tamoxifene (4OHT)-inducible system in which a chimeric RAS oncogene 






Klhl14-AS expression was measured by qRT-PCR, revealing that the lncRNA is strongly 
downregulated by RAS oncogenic activation (Fig 1D). 
 H-RAS
V12
FRTL-5 is a chronically Ras-transformed cell line, showing characteristics of thyroid cancer 
cells (31,32). Klhl14-AS expression was dramatically repressed in H-RAS
V12
 FRTL-5 with respect to 
parental FRTL-5 cells (Fig 1E).  
 Klhl14-AS expression in vivo was investigated in a mouse model of thyroid cancer where a transgenic 
BrafV600E oncogene is expressed in doxycycline (Dox)-dependent manner. BrafV600E activation 
induces poorly differentiated thyroid cancer with complete penetrance in a week of treatment (17). 
Klhl14-AS expression was analyzed by in situ hybridization on thyroid sections from doxycycline 
treated (+ Dox) and untreated (NT) mice. Neoplastic thyroids show staining for the long non-coding 
RNA weaker respect to the controls (Fig 1F). The downregulation of Klhl14-AS expression was 
confirmed by qRT-PCR analysis on total RNA extracted from pools of treated or untreated thyroids, 
confirming a dramatic decrease in neoplastic thyroids (Fig 1G). As both the in vitro and in vivo systems 
converge on the activation of MAPK, it is likely that such pathway could be responsible for Klhl14-AS 
down-regulation. To verify this hypothesis, we selected two human thyroid cancer cell lines, ACT-1 
and Cal-62, characterized by N-RAS and KRAS mutation respectively (33). In both cell lines, the 
treatment with the MEK inhibitor U0126 up-regulates Klhl14-AS expression (Fig S1B) indicating that 
Ras represses the lncRNA through the activation of this pathway. 
These results taken together clearly show that KLHL14-AS is downregulated in thyroid neoplastic 
transformation, regardless of the system used.  
 
Klhl14-AS knockdown regulates thyroid cell differentiation and viability. 
In order to define the role of Klhl14-AS downregulation in thyroid carcinogenesis, we silenced Klhl14-






downregulation of all the Klhl14-AS transcript variants (15), silencing was performed with a LNA 
targeting a common region (Fig S2A and B).  Knocked-down cells were analyzed for thyroid 
differentiation by qRT-PCR, revealing that Klhl14-AS silencing causes the decrease of the entire set of 
analyzed markers, although at different extents. Indeed, the expression of Ttf1 transcription factor, 
Thyroperoxidase (Tpo) and thyroid-stimulating hormone receptor (Tshr) was weakly repressed while 
the transcription factors Foxe1 and Pax8 and the functional markers Thyroglobulin (Tg) and 
Sodium/Iodide Symporter (Nis) showed the most dramatic down-regulation (Fig 2A).  
Then, to investigate the role of Khl14-AS in thyroid cell proliferation, we performed trypan blue 
exclusion assay, observing an increased percentage of viable cells upon Klhl14-AS down-regulation 
(Fig 2B). Besides, MTS assay confirmed that the lncRNA decrease causes a boost in cell metabolic 
activity (Fig 2C). Moreover, Klhl14-AS-silenced FRTL-5 cells show an increase in both Ki67 positive 
nuclei (Fig 2D, E) and Ki67 expression levels (Fig S2C) thus further suggesting the involvement of this 
lncRNA in the regulation of thyroid cell proliferation. To confirm these data to human thyroid cells, we 
knocked-down the reported human transcript in the wild type Nthy-ori 3-1 cells (Fig S2D and E), 
where we observed a significant reduction mainly in FOXE1 and PAX8 expression levels (Fig 2F). 
Besides, KLHL14-AS-silenced Nthy-ori 3-1 show an increase in cell proliferation and metabolic 
activity, similarly to what observed in FRTL-5 cells (Fig 2G, H). 
 
Klhl14-AS is a miR-182-5p and miR-20a-5p target  
The ability of Klhl14-AS knockdown to downregulate a set of differentiation-related genes is 
suggestive of ceRNA role. To verify this hypothesis, we used a comparative approach to identify 
candidate miRNA binding sites on the Klhl14-AS transcript reasoning that developmentally important 
miRNA binding sites on the lncRNA should be conserved in vertebrates. We, therefore, aligned 






identifying a highly conserved regions of 93 nucleotides resulting identical in the three mammalian 
species and sharing 85% identity with zebrafish (Fig S3A). Interestingly, this region is contained within 
the ultraconserved region uc.428 (34). We, then, run the PITA program with default parameters to 
predict miRNA binding sites on the conserved transcript fragments and took into account only those 
miRNAs predicted to bind on the conserved sequences in all the species. This analysis resulted in the 
selection of MIR182-5p and MIR20a-5p (Fig S3B and C and Table S4).  
Next, we validated Klhl14-AS as both Mir182-5p and Mir20a-5p target, by cloning the highly 
conserved region (HCR) in luciferase (Luc) reporter vector in both sense and antisense orientation 
(Klhl14-AS HCR and Klhl14-AS HCR-AS). Reporter constructs were transfected in HeLa cells together 
with miR-182-5p, miR-20-5p or control miRNA mimics. Luciferase assay showed that Klhl14-AS HCR 
luminescence is reduced by both Mir182-5p and miR-20a-5p mimics compared to the control, while 
Klhl14-AS HCR-AS activity is only barely affected by both miRNA mimics (Fig 3A). We evaluated 
endogenous Klhl14-AS responsiveness to Mir182-5p and Mir20a-5p in FRTL-5 cells, revealing that 
Klhl14-AS was down-regulated by either Mir182-5p or Mir20a-5p overexpression, even if at different 
extent. Indeed, Mir182-5p is more efficient than Mir20a-5p in inducing Klhl14-AS down-regulation 
(Fig 3B).  
Furthermore, we knocked-down MIR182-5p and MIR20a-5p with specific LNAs in the human PTC 
cell lines TPC1 and BCPAP, where they have been reported to be upregulated (35,36). In both cell 
lines, microRNA inhibition leads to an increase of Klhl14-AS levels (Fig 3C). TPC1 were also tested 
for viability and proliferation, showing a decrease of both parameters (Fig 3D, E). 
To check if Klhl14-AS directly interacts with Mir182-5p and Mir20a-5p, we performed a RNA pull-
down. Cytoplasmic extracts of FRTL-5 were incubated with streptavidin magnetic beads conjugated 
with biotinylated DNA oligonucleotides complementary to Klhl14-AS. Antisense LacZ 






Mir20a-5p and AGO2 protein were recovered, or highly enriched, only in samples obtained with 
Klhl14-AS specific oligos (Fig 3F-I). Interaction specificity was confirmed by the absence of the 
unrelated Mirlet7a in the same fraction (Fig S4). This result indicates that Klhl14-AS physically 
interacts with Mir182-5p, Mir20a-5p and AGO2, further suggesting that it might act as a decoy for 
these miRNAs. 
 
miR-182-5p and miR-20a-5p target thyroid-relevant genes 
To search for possible genes cross-talking with Klhl14-AS, we looked for thyroid-specific genes among 
Mir182-5p and Mir20a-5p predicted targets, identifying Pax8 as a putative target of both miRNAs. In 
addition Bcl2, another well-recognized player of thyroid differentiation and homeostasis (14,37) is 
predicted as miR-182-5p target (Table S5). We show that endogenous Pax8 is down-regulated by 
Mir182-5p and Mir20a-5p mimics at both mRNA and protein level, thus validating Pax8 as target of 
both miRNAs. At the same time, we demonstrated that Mir182-5p efficiently down-regulates Bcl2, as 
expected (Fig 4A, B). We then cloned for each gene the MREs-containing region (MCR), namely 
3'UTR of Pax8 and CDS of Bcl2, downstream to Luc reporter gene. The anti-sense sequences were 
used as controls. Reporter constructs were co-transfected in HeLa with either miR-182-5p or miR-20a-
5p, revealing that Pax8 MCR construct is repressed by both miRNAs (Fig 4C), and that Bcl2 MCR is 
targeted by Mir182-5p (Fig 4D), thus confirming both genes as Mir182-5p targets, with Pax8 being 
also targeted by Mir20a-5p. 
 
Klhl14-AS acts as ceRNA for Pax8 and Bcl2 
We wondered if the downregulation of thyroid differentiation markers caused by Klhl14-AS silencing 
could be mediated by the above outlined miRNA-lncRNA-mRNA cross-talk.  










 FRTL-5 and H-RAS
V12
FRTL-5 (18). Pax8 has also been 
shown to be repressed in the BrafV600E-driven thyroid cancer mouse model (17) and in most human 
thyroid cancer cell lines (38-41). Nevertheless, these data were independently confirmed by a new set 
of experiments (Fig S5 A-D). 
The expression of Bcl2 was measured in our thyroid cancer models, observing that it is severely 




 FRTL-5, in H-RAS
V12
 FRTL-5 (Fig 5A,B) in vivo, in 
doxycycline-dependent BrafV600E-induced thyroid cancer (Fig 5C) and in human thyroid cancer cell 
lines, (Fig 5D), thus showing that it follows the same trend as Klhl14-AS and Pax8. 
We have shown that Klhl14-AS downregulation strongly represses Pax8 expression (Fig 2B). Silencing 
the lncRNA in FRTL-5 and Nthy-ori 3-1 cells resulted in dramatic repression of Bcl2 levels as well 
(Fig 5E). 
To verify if Pax8 and Bcl2 downregulation induced by lncRNA knockdown requires the presence of 
miRNAs, we performed Klhl14-AS silencing together with Dicer silencing, observing that Pax8 and 
Bcl2 levels resulted de-repressed by Dicer knocking-down (Fig 5F).  
Moreover, we tested the ability of Klhl14-AS to acts as miRNA decoy by overexpressing the lncRNA 
in the presence of Mir182-5p and Mir20a-5p mimicks, showing that Pax8 and Bcl2 expression are 
rescued by Klhl14-AS overexpression (Fig 5G). 
As ceRNA mechanisms act at post-transcriptional level, we tested the effects of Klhl14-AS knockdown 
in the presence of Actinomycin D (Acto-D). Figure 5G shows that though Acto-D treatment represses 
the expression of all the genes analyzed, the knockdown of Klhl14-AS is still able to exert an inhibitory 
effect (Fig 5H). These results taken together strongly suggest that this lncRNA acts through a post-
transcriptional and miRNA-mediated decoy mechanism.  
To explore if Pax8 and Bcl2 play a role in the generalized loss of differentiation caused by Klhl14-AS 






both Pax8 and Bcl2 rescue the expression of all differentiation markers reduced by Klhl14-AS 
silencing, including endogenous Pax8 and Bcl2 (Fig 5I). Differentiation markers expression was not 
increased by Pax8 or Bcl2 overexpression in the presence of control LNA (Fig S6B). 
 
Klhl14-AS, PAX8 and BCL2 correlation in human thyroid cancer 
RNAs acting as ceRNA usually show similar trends of expression. We have shown that this is the case 
for Klhl14-AS,  PAX8 and BCL2 in experimental cancer models. Thus we investigated such issue in 
human thyroid cancer samples. PAX8 and BCL2 resulted invariably down-regulated in all ATC samples 
analyzed (Fig 6A). Conversely, in PTC samples we observed a larger range of values of PAX8 
expression with a median lower in PTC than normal thyroids (Fig 6B), while BCL2 shows a more 
homogeneous trend with a clear reduction of its median in PTC compared to healthy thyroids (Fig 6C). 
By combining these data with those already obtained for Klhl14-AS (Fig. 1A) it is worth noting that 
both PAX8 and BCL2 show a positive correlation with the lncRNA (Fig 6D,E) in the analyzed PTC 
samples. 
To confirm these data on a wider set of samples, we interrogated the GEPIA database 
(http://gepia.cancer-pku.cn/index.html https://academic.oup.com/nar/article/45/W1/W98/3605636), for 
differential expression of PAX8, BCL2 and KLHL14-AS between normal and neoplastic thyroid tissues, 
observing that all three genes are downregulated in thyroid cancer (Fig S7). 
Therefore, PAX8, BCL2 and KLHL14-AS show a similar behaviour in all the thyroid cancer models 
analyzed and in a large number of human thyroid carcinomas, as expected accordingly to ceRNA 
hypothesis. 
 
miR-182-5p and miR-20a-5p are upregulated in thyroid cancer 






both MIR182-5p and MIR20a-5p have been reported to be upregulated in thyroid cancer (35,36,42). To 
confirm this trend in our samples, we measured MIR182-5p and MIR20a-5p expression in seven of the 
PTC biopsies already analyzed for KLHL14-AS expression, observing that both miRNAs are increased 
in cancer with respect to the normal tissue (Fig 7A, B). Both miRNAs resulted up-regulated also in all 
the six ATC samples analyzed, (Fig 7C) and in human thyroid cancer cell lines (Fig 7D). 
Subsequently, we evaluated Mir182-5p and Mir20a-5p expression in the neoplastic-transformation 
models. Both miRNAs resulted up-regulated by RAS chronic activation in H-RAS
V12
FRTL-5 (Fig 7E).  
They also show a dramatic increase in doxycycline-induced BrafV600E-dependent thyroid cancer in 
mouse (Fig 7F).  
Therefore, these results clearly demonstrate that the expression of MIR182-5p and MIR20a-5p in 
cancer shows an opposite regulation with respect to that of KLHL14-AS, PAX8 AND BCL2, strongly 
suggesting that MIR182-5p and MIR20a-5p could play a role in the downregulation of the three genes 
in thyroid cancer, likely mediating a ceRNA circuitry.  
In conclusion, our data taken together indicate a cross-talk between KLHL14-AS and PAX8/BCL2 
mediated by MIR182-5p and MIR20a-5p in normal as well as in transformed thyroid cells.  
 
Discussion 
The differentiation status of neoplastic cells is a general measure of tumor malignancy, being lost in the 
most advanced and aggressive form of most cancer types. In thyroid cancer, the presence of 
differentiated cells is even more important, as their unique ability of capturing iodine can be used to 
treat patients with radioiodide after surgery, to eradicate residual and/or metastatic cancer cells. Poorly 
differentiated and anaplastic thyroid cancers lack this differentiated function and hence radioiodide 
treatment is not effective (43). Here we describe for the first time the role of a long noncoding RNA, 






maintenance of a fully differentiated state of cultured thyroid cells. By using multiple experimental 
tools, we show that KLHL14-AS is drastically repressed in human thyroid cancer biopsies and cell 
lines, and shows a similar behaviour in experimental models of thyroid transformation, regardless the 
species and the system used, in vivo or in vitro. This univocal behavior is indicative of the robustness of 
such data.  
There are several lncRNA playing key roles in the regulation of cell differentiation, well described for 
myogenesis, and for other cell types (44,45). One of the most frequent mechanisms of lncRNAs action 
in differentiation-related circuits is to act as decoys for miRNAs targeting master regulators of gene 
expression programs. This appears to be the case also for Klhl14-AS, that we show to compete with 
Pax8, an essential regulator of thyroid differentiation, for the binding to Mir182-5p and Mir20a-5p and 
with Bcl2, a survival factor essential in thyroid development (14,37) for the binding to Mir182-5p.  
Thyroid neoplastic rodent models in vitro and in vivo revealed that Klhl14-AS is severely down-
regulated in carcinogenesis. These data, together with KLHL14-AS repression more homogeneous and 
dramatic in ATC than in PTC samples, strongly suggest that the loss of this lncRNA is strictly related 
to the differentiation state. This has been confirmed in rat and human wild type cultured thyroid cells, 
in which differentiation markers decrease upon the lncRNA inhibition, indicating that KLHL14-AS 
down-regulation could be one of the primary events rather than a consequence of thyroid neoplastic 
transformation. Moreover, knocking-down of Klhl14-AS also induces an increase in cell viability and 
proliferation, two crucial events in cancer development, thus supporting a tumor-suppressor role for 
this lncRNA. 
MIR182-5p and MIR20a-5p have been already reported to be up-regulated in thyroid cancer (35,36,42), 
with our data confirming this trend in human samples and in experimental models. We show that both 
miRNAs are increased upon thyroid transformation thus showing an inverse correlation with the 






MIR182-5p and MIR20a-5p increase is related to advanced and less differentiated cancers. It is 
noteworthy that inhibition of both miRNAs increase the endogenous lncRNA levels in papillary thyroid 
cancer cell lines, supporting our hypothesis that KLHL14-AS down-regulation in thyroid cancer is 
mediated by MIR182-5p and MIR20a-5p. In addition, the physical interaction observed between 
Klhl14-AS, AGO2 and both miRNAs indicates that Klhl14-AS acts as decoy for Mir182-5p and 
Mir20a-5p. This is confirmed by the ability of Klhl14-AS to rescue Pax8 and Bcl2 repression exerted 
by the two miRNAs. 
Notably, here we demonstrate that two thyroid-relevant genes, Pax8 and Bcl2, are Mir182-5p targets, 
and that Pax8 is also targeted by Mir20a-5p. Further, mRNAs of both PAX8 and BCL2 show a positive 
correlation with KLHL14-AS in human thyroid cancers. Accordingly, PAX8 has already been reported 
as candidate target of Mir182-5p and Mir20a-5p (46), while BCL2 has been validated as Mir182-5p 
target in prostate cancer (47). We show that the effects of Klhl14-AS on differentiation are miRNA-
mediated and exerted at post-transcriptional level, with Pax8 and Bcl2 being the main targets. Indeed, 
re-expression of either Pax8 or Bcl2 rescues differentiation markers expression, in particular of Nis, 
thus corroborating the proposed mechanism . 
These evidences allow us to propose that a ceRNA network involving KLHL14-AS, PAX8 and BCL2 
acts in normal cells by buffering the expression of essential cell regulators, being instead deranged in 
thyroid carcinogenesis. Moreover, we observed that the interaction between these three genes and 
MIR182-5p and MIR20a-5p is conserved in human, mouse and rat models, highlighting that it could 
represent a very relevant mechanism supporting thyroid cancer onset and development. Both miRNAs 
target indeed an ultraconserved sequence of the lncRNA, found identical in the three species and highly 
conserved also in zebrafish, suggesting that such network is under a strong positive selection. 
In conclusion, our work sheds light on new players and networks involved in thyroid differentiation 






and/or MIR182-5p and MIR-20A-5p as novel thyroid carcinoma biomarkers. Finally, it would be 
interesting to evaluate if the inhibition of their crosstalk may be exploited as a new therapeutic 
approach in fighting the most advanced forms of thyroid carcinoma. 
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Figure Legends  
 
Fig 1. Klhl14-AS is downregulated in thyroid cancer. A. Klhl14-AS expression values of 12 PTC and 
their corresponding healthy samples reported as 2^-ΔCt in scatter dot plot. The median with the 
interquartile range is shown. B. Klhl14-AS expression in ATC samples and in a pool of healthy thyroids 
(HT), reported as Log10 of the 2^-ΔΔCt values. C. Klhl14-AS expression in thyroid cancer cell lines 





treated for 24 hours with vehicle (NT) or Tamoxifene (+4OHT) to induce Ras oncogenic activation. E. 
Klhl14-AS levels in parental FRTL-5 cells and H-RAS
V12
FRTL-5. Data in D and E are shown as Log10 
of the 2^-ΔΔCt values. F. Klhl14-AS expression analyzed by in situ hybridization in Tg-rtTA-TetO-
BrafV600E mouse thyroids. Mice were treated with doxycycline (+DOX) or left untreated (NT). 200x 
and 1000x magnifications are shown.  G. Klhl14-AS was measured on pools of untreated (NT) and 
treated (+DOX) thyroids. All data are shown as means ± SD. * p< 0.05; ** p < 0.01; *** p < 0.001. 
 
 Fig 2. Klhl14-AS knockdown affects thyroid cells differentiation and viability. A. Klhl14-AS was 
knocked-down in FRTL-5 using specific LNA Gapmers (Khl14-AS LNA)or control LNA (ctr LNA). 
Thyroid differentiation markers levels were evaluated through qRT-PCR. For each gene, value 
obtained in ctr LNA-transfected cells was set at 1 (dotted line). B. Control and Klhl14-AS knocked-
down FRTL-5 were counted upon Trypan blue staining. The number of viable and dead cells is 
expressed as percentage of the total counted cells. C. MTS assay performed on the samples shown in B. 
Absorbance values on the graph represent the average of four replicates. D. Ki67 positive nuclei 
percentage of control and Klhl14-AS knocked-down FRTL-5. E. Ki67 immunofluorescence of control 
and Klhl14-AS knocked-down FRTL-5. Scale bar represents 50µm. F. KLHL14-AS was knocked-down 
in Nthy-ori 3-1 using specific LNA Gapmers (KLHL14-AS LNA) or control LNA (ctr LNA). Thyroid 
differentiation markers evaluation was performed as in A. G. Control and Klhl14-AS knocked-down 
Nthy-ori 3-1 were counted upon Trypan blue staining. The number of viable and dead cells is 
expressed as percentage of the total counted cells. H. MTS assays performed on the samples shown in 
G. Absorbance values on the graph represent the average of four replicates. The data are representative 
of three independent experiments. All data are shown as means ± SD. * p< 0.05; ** p < 0.01; *** p < 
0.001. 
 
Fig 3. Klhl14-AS is target of miR-182-5p and miR-20a-5p. A. Luciferase activity of pGL3control 
vector containing Klhl14-AS highly conserved region (HCR) or its antisense sequence (HCR AS) co-
transfected with control (miR-ctr) or specific miRNA (Mir182-5p and Mir20a-5p) mimics. B. 
Endogenous Klhl14-AS levels in FRTL5 transfected with control, Mir182-5p and Mir20a-5p mimics. 
C. Klhl14-AS expression in TPC1 and BCPAP transfected with control (neg.ctr LNA) or specific 
miRNA inhibitors (MIR182-5p LNA and MIR20a-5p LNA). D. TPC1 cells transfected as in C were 
counted upon Trypan blue staining. The number of viable and dead cells is expressed as percentage of 






graph represent the average of four replicates. F. Klhl14-AS pull-down performed in FRTL-5 with 
antisense DNA oligonucleotides complementary to Klhl14-AS. Beads conjugated with LacZ 
oligonucleotides (LacZ) or unconjugated beads (BO) were used as controls. Recovered Klhl14-AS from 
input and pulled-down extracts was measured by qRT-PCR. G. Western blot analysis of AGO2 and 
ACTIN from input and pulled-down extracts. H. Mir182-5p recovery indicated as the percentage of the 
input. I. Mir20a-5p recovery shown as in F. Input represents 10% of the extract used for the pull-down.  
The data are representative of three independent experiments. All data are shown as means ± SD. * p< 
0.05; ** p < 0.01; *** p < 0.001.. 
 
Fig 4. Validation of Pax8 and Bcl2 as miRNAs targets. A. Endogenous levels of Pax8 and Bcl2 
transcripts in FRTL-5 evaluated after control (miR-ctr), Mir182-5p and Mir20a-5p mimics transfection 
by qRT-PCR. B. Western blot analysis of PAX8 and BCL-2 of samples transfected as in A (left panel) 
and the respective densitometric analysis (right panel). C. Luciferase activity of pGL3control vector 
containing MRE-containing region (MCR) of rat Pax8 transcript or its antisense sequence (MCR AS) 
co-transfected with control (miR-ctr) or specific miRNA (Mir182-5p and Mir20a-5p) mimics. D. 
Luciferase activity of pGL3 control vector containing MCR of rat Bcl2 transcript or its antisense 
sequence (MCR AS) co-transfected with control (miR-ctr) or specific Mir182-5p mimic. The data are 
representative of three independent experiments. All data are shown as means ± SD.* p< 0.05; ** p < 
0.01; *** p < 0.001. 
 





FRTL-5 treated for 24 hours with vehicle (NT) or Tamoxifene (+4OHT) to induce Ras 
oncogenic activation. B. Bcl2 levels in parental FRTL-5 and H-RAS
V12
FRTL-5. C. Bcl2 in Tg-rtTA-
TetO-BrafV600E mouse thyroids. Mice were treated with doxycycline to induce thyroid cancer 
(+DOX) or left untreated (NT). D. Bcl2 expression levels in thyroid cancer and normal human cell 
lines. E. Bcl2 expression in control (ctr LNA) and Klhl14-AS LNA transfected FRTL-5 and Nthy-ori 3-
1. F. Pax8 and Bcl2 expression in FRTL-5 transfected with control or Klhl14-AS LNA together with 
control or Dicer specific siRNA (ctr siRNA and Dicer siRNA). Data are shown as fold change of 
ctrLNA+ctrsiRNA sample. G. Pax8 and Bcl2 expression in FRTL-5 transfected with Mir182-5p or 
Mir20a-5p mimics together with pCEFLKlhl14-AS or empty vector (ev). H. Thyroid differentiation 
markers expression in control and Klhl14-AS silenced FRTL-5 treated with Actinomycin D (Acto-D). I. 
Thyroid differentiation markers expression in FRTL-5 transfected with control (ctr LNA) and Klhl14-
AS LNA, in combination with pCEFLPax8, pCEFLBcl2 or empty vector. Primers used for Pax8 and 
Bcl2 do not amplify ectopic mRNAs being designed on UTR of both genes. Data are shown as fold 
change of ctrLNA+ev sample. All data in the figure are obtained through qRT-PCR and are shown as 
means ± SD.* p< 0.05; ** p < 0.01; *** p < 0.001. 
 
Fig 6. Pax8 and Bcl2 expression positively correlates with that of Klhl14-AS in human thyroid 
cancer. A. Relative expression of Pax8 and Bcl2 in ATC samples and in a pool of healthy thyroids 
(HT). Data are shown as means ± SD. B. Pax8 expression values in 12 PTC and their corresponding 
healthy samples reported as 2^-ΔCt in scatter dot plot. The median with the interquartile range is 






and Pax8 expression values in the 12 PTC samples analyzed. Pearson's correlation coefficient tests 
were performed usign GraphPad Software. E. Correlation analysis of Klhl14-AS and Bcl2 expression 
values in the 12 PTC samples analyzed as described for Pax8 in D. Data are obtained through qRT-
PCR and are shown as means ± SD. * p< 0.05; ** p < 0.01; *** p < 0.001.  
 
Fig 7. MIR182-5p and MIR20a-5p are upregulated in thyroid cancer. A. MIR182-5p expression 
values in 6 PTC and their corresponding healthy samples reported as 2^-ΔCt in scatter dot plot. The 
median with the interquartile range is shown. B. MIR20a-5p expression values were analysed as in A. 
C. MIR182-5p and MIR20a-5p expression in ATC samples and in a pool of healthy thyroid tissues, 
arbitrarily set as 1 (dotted line). D. Relative expression of MIR182-5p and MIR20a-5p in thyroid cancer 
cell lines. The expression was compared to that measured in a pool of healthy thyroid tissues, 
arbitrarily set as 1. The data are shown as Log10 of the 2^-ΔΔCt values. E. Mir182-5p and Mir20a-5p 
levels in parental FRTL-5 and H-RAS
V12
FRTL-5. F. Mir182-5p and Mir20a-5p expression in thyroids 
from Tg-rtTA-TetO-BrafV600E mice treated with doxycycline (+DOX) or left untreated (NT). All data 
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